PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

Similar documents
PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life

Anticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO

Care of the Dying Management in Severe Renal Failure

Care of the Dying Management in Severe Renal Failure

ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT

Symptom Management Guidelines for End of Life Care

PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE

Renal Prescribing at End of Life Guidance for Anticipatory prescribing for patients in renal failure (egfr<30) at the end of life

Supportive Care. End of Life Phase

Algorithms for Symptom Management. In End of Life Care

[Type text] Anticipatory Medication STAT dose and Syringe Driver Guidance [Type text]

Renal Palliative Care Last Days of Life

EAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

End of life prescribing guidance

PENNINE LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

GUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT (estimated glomerular filtration rate<30)

Syringe driver in Palliative Care

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL

Care in the Last Days of Life

SYRINGE DRIVER MEDICATIONS

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

ALLERGIES/ SENSITIVITIES This section must be completed before prescribing/administering any drug

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

Diamorphine 4 hour. alfentanil (500microgram/mL) Calculated by dividing 24 hour oral morphine dose by 30

Anticipatory prescribing and end of life considerations. Dr Stephanie Lippett

Doncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary

Guidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth)

SUBCUTANEOUS AS REQUIRED & SYRINGE PUMP PRESCRIPTION & ADMINISTRATION RECORD (SPAR) Name: Address: Postcode: Date of Birth: NHS Number:

1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER

Care of dying adults in the last days of life. Improving care at the very end of life.

Palliative care for heart failure patients. Susan Addie

INTEGRATED CARE PATHWAY (ICP) FOR THE DYING ADULT

Conservative Management of Uraemia

Palliative Care Out-of-hours. A resource pack for West Dorset. Contents:

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-

Essential Syringe Driver Training for T 34. Elaine Bird St Luke s Hospice

Palliative Care Impact Survey

Syringe Drivers. Back to top

SYMPTOM CONTROL IN THE LAST DAYS OF LIFE. Bradford, Airedale, Wharfedale & Craven

End Stage Liver Disease Regional Audit Casenote Survey

Waterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC)

Clatterbridge Centre for Oncology

BJF Acute Pain Team Formulary Group

End of Life Care. Dr Anne Garry Consultant in Palliative Medicine

Coversheet for Network Site Specific Group Agreed Documentation

Implementing the recommendation on medication management and symptom control

Palliative Prescribing - Pain

This survey aims to look at individual practice and can be completed by any healthcare professional.

MND Just in Case kit Information for GPs

We would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients.

The last days of life in hospital and at home

Using syringe pumps in palliative care

Policy/Standard Operating Procedure/ Clinical Guideline. ELHT/CP22 Version 5.1. ELHT/CP22 Version 4.1

Managing Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital.

Regional Renal Training

Symptom Control in the Community Setting. Dr Andrew Tysoe-Calnon

BREATHLESSNESS MANAGEMENT

Lothian Palliative Care Guidelines POCKET EDITION 2004

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

Overview of Essentials of Pain Management. Updated 11/2016

Respiratory Secretions. Care in the last 72 hours of life Paul Tait, pharmacist

Berkshire Adult Palliative Care Guidelines - End of Life Care GL110


Pain management in Paediatric Palliative Care. Dr Jane Nakawesi 14 th August 2017

Understanding pain in 5 minutes

East Kent Prescribing Group

Palliative Care. Pocketbook 4

Planning for the future; A guide to symptom control at end of life in advanced dementia

CARE OF THE DYING PATIENT WITH ESKD ELIZABETH JOSLAND - RSC CNC

Palliative Care Formulary

Palliative Care. Anticipatory Prescribing Guidelines & June Gippsland Region Palliative Care Consortium Clinical Practice Group

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.

Palliative care for patients with brain cancer

BACKGROUND Measuring renal function :

Isle of Wight Syringe Driver Compatibility Guidelines

Target audience: The target audience for this guidance are: GPs Care home managers and nurses, District nurses, and Specialist Palliative Care teams.

Approach to symptom control near the end-of-life

Eastern Health and Social Services Board Palliative Care

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES

Berkshire West Area Prescribing Committee Guidance

1 (ix) Pain control. What responsibilities do you assume when you prescribe analgesia?

PRIMARY CARE PALLIATIVE CARE FORMULARY

GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline

GUIDELINES AND AUDIT IMPLEMENTATION NETWORK

Guidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).

Agitation. Susan Emmens Palliative Care Clinical Nurse Specialist

General Palliative Care Guidelines for the Management of Pain at the End of Life in Adult Patients

Pain management in palliative care. Dr. Stepanie Lippett and Sister Karen Davies-Linihan

What s New 2003? What new treatments? What have you discontinued? More information please!

West Midlands Palliative Care Physicians. Palliative care. Guidelines for the use of drugs in symptom control

Managing dying with chronic heart failure

GUIDELINES FOR THE MANAGEMENT OF DELIRIUM IN ADVANCED CANCER

Regional Breathlessness Audit - Case Note Survey. 1. Introduction. Regional Breathlessness Audit - Case Note Survey. 2.

NHS Grampian. Care Plan Palliative & Supportive. Acute Care Settings

Managing Symptoms in End of Life Care

Transcription:

PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member of the team has a responsibility to check that the intended dose is safe for the individual person. Knowledge of previous opioid dose is essential for the safe use of these products. Advice should be sought if prescribing outside of these guidelines or when the limits of own expertise are reached (NPSA/2008/RRR05) CONTACT THE PALLIATIVE CARE TEAM FOR ADVICE IF: The person has moderate to severe renal failure. The person has new severe pain or pain that has persisted after 24 hours on a syringe driver. YES PERSON IS TAKING ORAL MORPHINE NO Continue with oral morphine if tolerated OR if not tolerated: Convert total daily dose of oral morphine to subcutaneous route by dividing by 2 and prescribe this dose subcutaneously via a syringe driver over 24 hours (see example (a) below). Prescribe a SC 4 hourly PRN breakthrough pain dose of morphine that is 1/6 th of the calculated total morphine dose in the syringe driver (see example (b) below). Reassess after 24 hours. If person has required additional morphine for breakthrough pain calculate dose required in syringe driver for next 24 hours by: Adding total breakthrough doses in previous 24 hours to current syringe driver dose to give new 24 hour dose NOTE: the new syringe driver dose MUST NOT be increased by more than 50% of previous 24 hours morphine dose Ensure breakthrough dose remains at 1/6 th of syringe driver dose. Maximum dose of morphine in syringe driver is 180mg and maximum breakthrough dose is 30mg (due to volume capacity) YES If oral route tolerated give morphine 5mg OR Prescribe and give morphine 2.5 mg to 5mg SC STAT Prescribe morphine 10 mg via syringe driver over 24 hours Prescribe morphine 2.5 to 5 mg SC 4 hourly PRN for breakthrough pain. Person has pain NO Prescribe in anticipation of symptoms morphine 2.5 mg to 5 mg SC 4 hourly PRN Example (a) syringe driver dose Converting from oral morphine to syringe driver E.g. Zomorph 60 mg 12 hourly = 120 mg 120mg/2 = 60 mg Dose of morphine subcutaneously via syringe driver over 24 hours = 60 mg Example (b) calculating breakthrough dose The breakthrough dose is 1/6th of total daily morphine dose E.g. Person requires 60 mg morphine via syringe driver over 24 hours 60/6 = 10 mg morphine SC PRN Acknowledgement to Halton, St Helens and Knowsley palliative care teams for permission to adapt their guidelines 1

PAIN MANAGEMENT Persons established using fentanyl patches Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member of the team has a responsibility to check that the intended dose is safe for the individual person. Knowledge of previous opioid dose is essential for the safe use of these products. Advice should be sought if prescribing outside of these guidelines or when the limits of own expertise are reached (NPSA/2008/RRR05) DO NOT COMMENCE FENTANYL PATCHES FOR PAIN RELIEF IN THE DYING PHASE. If the person has severe renal dysfunction and requires additional pain relief seek advice on prescribing from the palliative care team. FENTANYL ESTABLISHED PAIN PRESENT DO NOT remove fentanyl patch continue and re-apply every 72 hours. PAIN CONTROLLED Prescribe SC opioid for breakthrough pain as needed. See table below. Prescribe adequate dose of SC breakthrough opioid analgesia as table below. Re-assess after 24 hours If 2 or more doses of SC breakthrough opioid are required in 24 hours, commence syringe driver. Use clinical judgement to assess and determine the 24 hour dose required in the syringe driver. This can be 50% to 100% of the total amount of s/c breakthrough opioid given in the previous 24hours. This is prescribed in addition to the fentanyl patch. OBTAIN SPECIALIST PALLIATVE CARE ADVICE REGARDING CALCULATING SUBSEQUENT PRN DOSE OF OPIOID S/C ONCE OPIOID IS REQUIRED IN SYRINGE DRIVER. Fentanyl patch strength Up to 4 hourly morphine SC PRN Up to 4 hourly oxycodone SC PRN 12 micrograms per hour 2.5 mg 1.25mg to 2.5mg 25 micrograms per hour 5 mg 2.5 mg 50 micrograms per hour 10 mg 5 mg 75 micrograms per hour 15 mg 10 mg When calculated syringe driver doses of morphine exceed 180mg; or morphine breakthrough doses exceed 30mg, diamorphine will need to be considered. Contact specialist palliative care team for advice. Acknowledgement to Halton, St Helens and Knowsley palliative care teams for permission to adapt their guidelines 2

NAUSEA & VOMITING for people without heart failure PRESENT ABSENT Taking anti-emetics Not taking anti-emetics Prescribe cyclizine 50mg SC stat dose and commence 150 mg via syringe driver over 24 hours Prescribe in anticipation of symptom cyclizine 50 mg SC 8 hourly PRN If symptoms persist ADD haloperidol 1.5 mg to 5 mg SC via syringe driver over 24 hours Seek advice via advice line number below HEART FAILURE: (reference - Cheshire and Merseyside Clinical Network: Guidelines for symptom control for adults with endstage heart failure January 2014) CYCLIZINE IS NOT RECOMMENDED IN PEOPLE WITH HEART FAILURE (Unless very short prognosis) Metoclopramide is first line (contra-indicated in gastro-intestinal obstruction; avoid or use with extreme caution in abdominal colic) Metoclopramide 10mg SC PRN plus initial dose of 30mg via syringe driver over 24 hours. If chemical causes of nausea and vomiting e.g. renal failure or medication Haloperidol 1.5mg to 3mg SC PRN plus haloperidol 1.5mg to 5mg via syringe driver over 24 hours Maximum 10mg in 24hours Or Levomepromazine 6.25mg SC 8 hourly PRN plus levomepromazine 6.25 mg to 12.5mg to 25 mg via a syringe driver over 24 hrs LEWY BODY DEMENTIA For people with Lewy Body dementia AVOID haloperidol, levomepromazine and metoclopramide Acknowledgement to Halton, St Helens and Knowsley palliative care teams for permission to adapt their guidelines 3

TERMINAL RESTLESSNESS & AGITATION The intention of sedation in palliative care is to relieve distress unconsciousness may occur but is not a desired outcome (refer to NPSA/2008/RRR011) PRESENT ABSENT Urinary retention and rectal distension from constipation are common reversible causes of agitation ensure these are excluded. Prescribe midazolam 2.5 mg to 5 mg SC PRN until syringe driver commenced. If 2.5 mg ineffective after 30 minutes, give a further 5 mg (total 7.5 mg in 1 hour). If person remains agitated seek medical review and contact Specialist Palliative Care Team for advice. If agitation likely to persist commence midazolam 10 mg to 20 mg SC via syringe driver over 24 hours. In addition prescribe midazolam 2.5 mg to 5 mg SC PRN 4 hourly. Prescribe in anticipation of symptom Midazolam 2.5 mg to 5 mg SC up to 4 hourly PRN. Maximum 30 mg in 24 hours To calculate the subsequent subcutaneous dose of midazolam over 24 hours: Calculate and add total dose of midazolam given on a PRN basis over previous 24 hours to current 24 hour dose via syringe driver. Increase the dose of midazolam accordingly up to 30 mg in syringe driver over 24 hours. Continue with PRN midazolam calculate dose as 1/6 th of syringe driver dose. If midazolam 30 mg in syringe driver is reached and symptoms are not controlled, please seek advice. Acknowledgement to Halton, St Helens and Knowsley palliative care teams for permission to adapt their guidelines 4

RESPIRATORY TRACT SECRETIONS It is important to start treatment as soon as symptoms occur PRESENT ABSENT Prescribe glycopyrronium 200 micrograms SC STAT and Commence syringe driver containing glycopyrronium 600 to 1200 micrograms over 24 hours. Prescribe in addition glycopyrronium 200 micrograms 6 hourly prn (maximum 2400 micrograms in 24 hours) Prescribe glycopyrronium 200 micrograms SC 4 hourly PRN (Maximum 2400 micrograms in 24 hours) Prescribing in anticipation of this common symptom may prevent delay in commencing treatment. If respiratory tract secretions persist over the next 24 hours, increase glycopyrronium to 2400 micrograms over 24 hours. This is a maximum dose. There is no benefit from additional PRN doses. NB- Hyoscine hydrobromide can be used as an alternative use 400 micrograms SC as PRN dose and 1200 micrograms via syringe driver over 24 hours Acknowledgement to Halton, St Helens and Knowsley palliative care teams for permission to adapt their guidelines 5

BREATHLESSNESS YES DISTRESSING BREATHLESSNESS NO Prescribe morphine 2.5 mg to 5 mg SC 4 hourly PRN and midazolam 2.5 mg SC 4 hourly PRN State on medicine chart/authorisation to administer chart that indication is breathlessness Prescribe PRN opioids & anxiolytic in anticipation of symptom Morphine 2.5 mg SC 4 hourly PRN and Midazolam 2.5 mg SC 4 hourly PRN Or if breathlessness is constant Morphine 5 mg to 10 mg via syringe driver over 24 hours (if previously taking oral opioid for breathlessness convert previous oral opioids dose - see pain algorithm) and Midazolam 5 mg to 10 mg via syringe driver over 24 hours. Acknowledgement to Halton, St Helens and Knowsley palliative care teams for permission to adapt their guidelines 6

PAIN MANAGEMENT For people established taking oral oxycodone Important it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member of the team has a responsibility to check that the intended dose is safe for the individual person. Knowledge of previous opioid dose is essential for the safe use of these products. Advice should be sought if prescribing outside of these guidelines or when the limits of own expertise are reached (NPSA/2008/RRR05) BOTH 3:2 AND 2:1 CONVERSIONS FROM ORAL OXYCODONE TO THE SUBCUTANEOUS ROUTE ARE USED. IN THE DYING PHASE USE 3:2 AS BELOW CONVERT ORAL OXYCODONE TO SUBCUTANEOUS ROUTE AS BELOW CALCULATE DOSE REQUIRED OVER 24 HOURS IN SYRINGE DRIVER: SYRINGE DRIVER DOSE = 2/3 RD OF ORAL DAILY DOSE. E.g. Oxycodone M/R 45 mg 12 hourly = 90 mg in 24 hours 2/3 rd of 90 mg = 60 mg Dose required in syringe driver = 60 mg CALCULATE DOSE OF OXYCODONE REQUIRED FOR RELIEF OF BREAKTHROUGH PAIN. BREAKTHROUGH DOSE = 1/6 TH DOSE IN SYRINGE DRIVER. E.g. Oxycodone 60 mg/24 hours in syringe driver = 10 mg oxycodone SC PRN 4 hourly RE-ASSESS AFTER 24HRS if person has required breakthrough analgesia calculate total amount given in previous 24 hours and increase dose in syringe driver by up to 50% of this amount. ENSURE THAT BREAKTHROUGH DOSE REMAINS 1/6 th of DOSE IN SYRINGE DRIVER Acknowledgement to Halton, St Helens and Knowsley palliative care teams for permission to adapt their guidelines 7